IRulya Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $211.28M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | $-12.31 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $-0.34 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.34 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | $-0.13 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 24, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 30, 2023 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 1, 2022 | Before market open | – | – | – |
Press releases
Announcements IRulya Therapeutics filed with the SEC
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
QUINCE THERAPEUTICS, INC., AND SUBSIDIARIES
Other events · EX-99.1 to Form 8-K
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Financial Statements as of and
Other events · EX-99.6 to Form 8-K/A
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in
Regulation FD disclosure · EX-99.2 to Form 8-K/A
Quince Announces Acquisition of Orphai and up to $187 Million Private
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Quince Therapeutics Announces Clinically Meaningful Improvements Across
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation May 18, 2026 A
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Quince Therapeutics Announces Topline Results from
Other events · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
Quince Therapeutics Completes Enrollment in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
Quince Therapeutics Provides Business Update and
Results of operations · EX-99.1 to Form 8-K
identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,”
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Quince Therapeutics Details Strategic Growth Plan with
Results of operations · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cortexyme Announces Agreement to Acquire Novosteo
Other events · EX-99.1 to Form 8-K